{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:41:46Z","timestamp":1790001706516,"version":"4.0.1"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the glucosuric, renal and haemodynamic effects of licogliflozin, a dual sodium\u2010glucose co\u2010transporter\u20101 and sodium\u2010glucose co\u2010transporter\u20102 inhibitor, in patients with chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multiple\u2010dose, parallel\u2010group, phase II mechanistic study randomized 53 participants (aged 18\u201378\u2009years, body mass index \u2264\u200950\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) with varying degrees of CKD or normal renal function to treatment with licogliflozin (50\u2009mg once daily) or placebo for 7\u2009days. The effects of licogliflozin on 24\u2010h urinary glucose excretion (UGE\n                      <jats:sub>24<\/jats:sub>\n                      ), renal function, haemodynamics, pharmacokinetics and safety were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Licogliflozin treatment for 7\u2009days significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.01) increased UGE\n                      <jats:sub>24<\/jats:sub>\n                      from baseline in participants with normal renal function (adjusted mean change: 41.8 [33.6, 49.9] g) or with mild (32.6 [24.1, 41.0] g), moderate A (35.7 [28.6, 42.9] g) or moderate B (20.3 [13.1, 27.5] g) CKD, but not in severe (6.2 [\u22120.71, 13.18] g) CKD. Licogliflozin reduced urinary electrolytes (sodium, potassium and chloride), blood pressure and urinary volume to varying extents among different groups. Significant increases in renin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05), angiotensin II (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05) and aldosterone (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.01) levels were observed. Adverse events were generally mild, and most commonly included diarrhoea (94%), flatulence (68%) and abdominal pain (21%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Licogliflozin treatment results in significantly increased UGE and favourable changes in urinary electrolytes and haemodynamics in patients with varying degrees of CKD (estimated glomerular filtration rate \u2265\u200945\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14327","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T11:10:04Z","timestamp":1611918604000},"page":"1182-1190","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium\u2010glucose co\u2010transporter\u20101 and sodium\u2010glucose co\u2010transporter\u20102, in patients with chronic kidney disease: A randomized trial"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-6726","authenticated-orcid":false,"given":"YanLing","family":"He","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Pachori","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Ma","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha E.","family":"Mendonza","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Amer","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Marbury","sequence":"additional","affiliation":[{"name":"Orlando Clinical Research Center  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002343"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31012-1"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60687-X"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05039-w"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70208-0"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.10.026"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1624582"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4654-7"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13654"},{"key":"e_1_2_10_14_1","unstructured":"Clin Pharmacol Ther. 108"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22764"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14248"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.170"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.06.003"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12425"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202218"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.01.010"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.02.003"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164112441190"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.512"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.560181"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.04.011"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.250"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4101-6"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0232-0"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000313363"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14327","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:31Z","timestamp":1761870271000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/dom.14327"],"URL":"https:\/\/doi.org\/10.1111\/dom.14327","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"2020-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}